FIELD: medicine.
SUBSTANCE: invention relates to a novel vanadium compound, which is a vanadium polymer derivative of general formula (I): (V=O)-(R)m (I), where V=O is vanadium ion VO2+, R – polymer residue, which is polyvinylpyrrolidone of formula
,
m – integer, which takes value from 1 to 2, n – integer, which takes value from 100 to 350. Also disclosed are use of a vanadium compound, a pharmaceutical composition and use thereof.
EFFECT: said compounds have hypoglycemic activity and can be used for treating type 1 or type 2 diabetes.
12 cl, 5 dwg, 3 ex
Title | Year | Author | Number |
---|---|---|---|
OXOVANADIUM COMPLEX WITH GLYCINE MANIFESTING HYPOGLYCEMIC ACTIVITY | 2007 |
|
RU2341528C1 |
PHARMACEUTICAL COMBINATION, COMPOSITION, AND COMBINED COMPOSITION CONTAINING GLUCOKINASE ACTIVATOR AND BIGUANIDE HYPOGLYCEMIC DRUG, AS WELL AS THEIR PREPARATION METHOD, AND THEIR USE | 2019 |
|
RU2780377C2 |
PHARMACEUTICAL COMPOSITION FOR TREATMENT OF TYPE 2 DIABETES MELLITUS AND MEDICINE ON ITS BASIS | 2009 |
|
RU2435593C2 |
HAEMORHEOLOGIC AGENT CAPABLE OF REDUCING INSULING RESISTANCE AND RESTORING BODY TOLERANCE TO GLUCOSE AND PHARMACEUTICAL COMPOSITION BASED ON SAID AGENT | 2007 |
|
RU2386634C2 |
PHARMACEUTICAL COMBINATION FOR TREATING AND/OR PREVENTING DISORDERS RELATED TO OVERWEIGHT AND/OR OBESITY, AND BASED METHOD OF TREATING | 2014 |
|
RU2552926C1 |
SOLID DOSED FORMULATION FOR TREATMENT OF PANCREATIC DIABETES | 2006 |
|
RU2333760C2 |
PHARMACEUTICAL COMPOSITION WITH ANTIDIABETIC EFFECT BASED ON OXOVANADIUM DERIVATIVE AND METHOD FOR IT PREPARING | 2001 |
|
RU2203656C1 |
METHOD FOR TREATING METABOLISM DISORDERS MAINLY DIABETES CASES AND DISEASES OR STATES RELATED TO DIABETES | 2000 |
|
RU2280447C2 |
PHARMACEUTICAL COMPOSITION POSSESSING ANTIDIABETIC, HYPOLIPIDEMIC, HYPOGLYCEMIC AND CHOLESTEROL LOWERING ACTION, WAY OF ITS RECEPTION AND WAYS OF TREATMENT OF SPECIFIED DISEASES | 2007 |
|
RU2361581C2 |
APPLICATION OF VANADIUM COMPOUNDS FOR MAINTAINING NORMOGLYCEMIA IN MAMMALS | 2012 |
|
RU2624495C2 |
Authors
Dates
2019-12-18—Published
2019-03-31—Filed